Marksans Pharma Limited — Others, 08-08-2025: Shareholders meeting

Marksans Pharma shareholders have approved all resolutions at the 33rd Annual General Meeting. Key approvals include the adoption of financial statements for the year ended March 31, 2025, and a dividend of Rs. 0.80 per equity share. Shareholders also approved the re-appointment of Mrs. Sandra Saldana and Mr. Mark Saldanha as Managing Director. The appointment of Mr. Srinivas Mishra as an Independent Director and the Secretarial Auditor was also confirmed. Amendments to the Employee Stock Option Scheme 2024 and the grant of ESOPs to subsidiary employees received shareholder consent. These decisions reinforce governance and align employee incentives.